IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Mombelli, Sarah ^a,b,c,d   Cochaud, Stéphanie ^a,b,e   Merrouche, Yacine ^c,d   Garbar, Christian ^c   Antonicelli, Frank ^d   Laprevotte, Emilie ^e,f   Alberici, Gilles ^e   Bonnefoy, Nathalie ^f   Eliaou, Jean François ^f,g   Bastid, Jérémy ^e   Bensussan, Armand ^a,b   Giustiniani, Jérôme ^c,d  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT JEAN GODINOT   (France)

^d EA7319 ^*  (France)

^e OREGA Biotech   (France)

^f INSERM   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN E; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; RAF PROTEIN; S6 KINASE;

APOPTOSIS; BIOPSY; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN E; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-17; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, INTERLEUKIN-17; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION;

EID: 84936874242     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11874     Document Type: Article

References (39)

1. Iwakura, Y., Ishigame, H., Saijo, S. & Nakae, S. Functional specialization of interleukin-17 family members. Immunity. 34, 149-62.
2. Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 9, 556-67 (2009).
3. Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 10, 479-89.
4. Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K. & O'Brien, R. L. gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 20, 353-7 (2008).
5. Onishi, R. M. & Gaffen, S. L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 129, 311-21 (2010).
6. Ouyang, W., Kolls, J. K. & Zheng, Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 28, 454-467 (2008).
7. Yang, B. et al. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 623759; doi: 10.1155 (2014).
8. Zhu, X. et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10 doi: 10.1186/bcr2195 (2008).
9. Chen, W. C. et al. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 63, 225-33 (2013).
10. Numasaki, M. et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101, 2620-7 (2003).
11. Nam, J. S. et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 10, 3915-23 (2008).
12. Cochaud, S. et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 3, 3456; doi: 10.1038/srep03456 (2013).
13. Bastid, J., Bonnefoy, N., Eliaou, J. F. & Bensussan, A. Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology. 3, 28273; e28273 (2014).
14. Huang, C. K. et al. Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappaB-mediated antiapoptotic pathway. Oncogene. 33, 2968-77 (2014).
15. Furuta, S. et al. IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med. 3, 78ra3116; doi: 10.1126/scitranslmed (2011).
16. King, A. J. et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 396, 180-3 (1998).
17. Mason, C. S. et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO. 18, 2137-48 (1999).
18. Ghayad, S. E. & Cohen, P. A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov. 1, 29-57 (2010).
19. Pullen, N. & Thomas, G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 410, 78-82 (1997).
20. Weng, Q. P. et al. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem. 273, 16621-9 (1998).
21. Porter, D. C. & Keyomarsi, K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res. 28, E101 (2000).
22. Wingate, H. et al. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 280, 15148-57 (2005).
23. Wang, X. D., Rosales, J. L., Magliocco, A., Gnanakumar, R. & Lee, K. Y. Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain. Oncogene. 22, 769-74 (2003).
24. Chung, A. S. et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med Sep. 19, 1114-23 (2013).
25. Younesi, V. & Nejatollahi, F. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells. Int Immunopharmacol. 23, 624-32 (2015).
26. Duong, M. T. et al. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 8, e1002538; doi: 10.1371/journal.pgen (2012).
27. Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595-8 (2001).
28. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 26, 2262-72.
29. Benatar, T. et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother. 59, 805-17 (2010).
30. Chin, Y. et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 12, 1463-6 (1992).
31. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-13 (2008).
32. Jung, J. S. et al. Association of IL-17RB gene polymorphism with asthma. Chest. 135, 1173-80 (2009).
33. Hagn, M. et al. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol. 183, 1838-45 (2009).
34. Wiedow, O., Schroder, J. M., Gregory, H., Young, J. A. & Christophers, E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 265, 14791-5 (1990).
35. Zhang, M., Zou, Z., Maass, N. & Sager, R. Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res. 55, 2537-41 (1995).
36. Sarra, M. et al. IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology. 58, 1436-50.
37. Dolgachev, V., Petersen, B. C., Budelsky, A. L., Berlin, A. A. & Lukacs, N. W. Pulmonary IL-17E (IL-25) production and IL-17RB+ myeloid cell-derived Th2 cytokine production are dependent upon stem cell factor-induced responses during chronic allergic pulmonary disease. J Immunol. 183, 5705-15 (2009).
38. Miyagaki, T. et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res. 17, 7529-38.
39. Mayer, C. et al. DNA repair capacity after gamma-irradiation and expression profiles of DNA repair genes in resting and proliferating human peripheral blood lymphocytes. DNA Repair. 1, 237-50 (2002).